Recently, the concomitant use of atezolizumab (anti-programmed death-ligand 1 (PD-L1) antibody) plus bevacizumab (anti-vascular endothelial growth factor (VEGF) antibody) was approved by the United States Food and Drug Administration (FDA) for first-line treatment of unresectable or metastatic HCC, based on the results of the IMbrave-150 study [11]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.